Market Research Reports and Industry Reports

Toxoplasmosis - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Toxoplasmosis - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Toxoplasmosis - Pipeline Review, H2 2017, provides an overview of the Toxoplasmosis (Infectious Disease) pipeline landscape.

Toxoplasmosis is a disease that results from infection with the Toxoplasma gondii parasite. Symptoms include body aches, swollen lymph nodes, headache, fever and fatigue. Risk factors include HIV/AIDS, chemotherapy and immunosuppressant drugs. Treatment includes an antimalarial drug and antibiotics.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Toxoplasmosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Toxoplasmosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Toxoplasmosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Toxoplasmosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 1, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Toxoplasmosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Toxoplasmosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Toxoplasmosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Toxoplasmosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Toxoplasmosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Toxoplasmosis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Toxoplasmosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Toxoplasmosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Toxoplasmosis - Overview
Toxoplasmosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Toxoplasmosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toxoplasmosis - Companies Involved in Therapeutics Development
AbbVie Inc
GlaxoSmithKline Plc
Novartis AG
Sanofi
Turing Pharmaceuticals AG
Toxoplasmosis - Drug Profiles
pyrimethamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
silver sulfadiazine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Histone Deacetylase for Toxoplasmosis and Other Parasitic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Toxoplasmosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDPK1 for Protozoal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DHFR for Toxoplasmosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
spiramycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
toxoplasmosis [type II delta KU80 RH strain] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
toxoplasmosis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
toxoplasmosis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRP-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRP-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TUR-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toxoplasmosis - Dormant Projects
Toxoplasmosis - Product Development Milestones
Featured News & Press Releases
Feb 03, 2016: Turing Pharmaceuticals Provides Key Facts to Congressional Oversight Committee
Jan 22, 2016: Turing Pharmaceuticals to Testify at Congressional Hearing on Drug Pricing
Dec 18, 2015: Continued Availability of Daraprim (pyrimethamine)
Nov 24, 2015: Texas Becomes Latest State ADAP to Add Daraprim (pyrimethamine) to Formulary
Oct 13, 2015: Turing Pharmaceuticals Announces Improvements in Daraprim Accessibility and Affordability
Sep 25, 2015: Keller Rohrback Investigates Turing Pharmaceuticals for Alleged Daraprim Price Gouging
Sep 24, 2015: Turing Pharmaceuticals Issues Statement on Daraprim Price Reduction
Sep 18, 2015: Turing Pharmaceuticals Provides Update On Availability Of Daraprim
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development for Toxoplasmosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Toxoplasmosis - Pipeline by AbbVie Inc, H2 2017
Toxoplasmosis - Pipeline by GlaxoSmithKline Plc, H2 2017
Toxoplasmosis - Pipeline by Novartis AG, H2 2017
Toxoplasmosis - Pipeline by Sanofi, H2 2017
Toxoplasmosis - Pipeline by Turing Pharmaceuticals AG, H2 2017
Toxoplasmosis - Dormant Projects, H2 2017

List Of Figures


Number of Products under Development for Toxoplasmosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Global Toxoplasmosis Diagnostics Market Country Shares and Segment Forecasts 2017-2021: Emerging Opportunities and Growth Strategies for Suppliers

The report presents a detailed analysis of the Toxoplasmosis diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Toxoplasmosis definition,

USD 4350View Report

Toxoplasmosis - Pipeline Review, H2 2017

Toxoplasmosis - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Toxoplasmosis - Pipeline Review, H2 2017, provides an overview of the Toxoplasmosis (Infectious Disease) pipeline

USD 2000View Report

Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Pipeline Review, H2 2017

Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Pipeline Review, H2 2017Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5)

USD 3500View Report

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H2 2017

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H2 2017According to the recently published report Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H2 2017; Neuronal

USD 3500View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Dec 2017
No. of Pages :44
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube